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ABSTRACT
Objective: Healthcare professionals (HCPs) are required to assess and train patients in the correct use
of inhalers but are often unable to demonstrate correct technique themselves. We sought to assess
the level of training required for HCPs to master and maintain device mastery when using two differ-
ent dry powder inhalers (DPIs). Methods: We conducted a randomized, un-blinded, crossover study
in undergraduate HCPs who undertook a six-step training procedure (intuitive use, patient informa-
tion leaflet, instructional video, individual tuition from expert, then two repeats of individual tuition)
for the use of Turbuhaler R© (an established device) and Spiromax R© (a newer device, reportedly easier
to use). Device mastery (absence of errors) was evaluated by expert assessors at each training step.
Maintenance of mastery was assessed 4± 1 week (visit 2) and 8 ± 2 weeks (visit 3) after initial training
(visit 1). Results: Of 516 eligible participants, 113 (22%) demonstrated device mastery prior to training
on Spiromax R© compared with 20 (4%) on Turbuhaler R© (p < 0.001). The median number of training
steps required to achieve mastery was 2 (interquartile range [IQR] 2–4) for Spiromax R© and 3 (IQR 2–
4) for Turbuhaler R© (p< 0.001). A higher number of participants maintained mastery with Spiromax R©
compared with Turbuhaler R©, at visits 2 and 3 (64% vs 41% and 79% vs 65%, respectively; p < 0.001).
Conclusions: There are significant differences in the nature and extent of training required to achieve
and maintain mastery for Spiromax R© and Turbuhaler R© devices. The implications on clinical practice,
device education delivery, and patient outcomes require further evaluation.
Introduction
Inhalers are the most commonly used devices to deliver
pharmacological treatments for asthma and chronic
obstructive pulmonary disease (COPD) [1]. Because cor-
rect use of inhalers is central to effective therapy, poor
inhaler technique not only compromises disease control
[2] but also consequently increases the economic bur-
den of asthma management [3]. Unfortunately, incorrect
inhaler use remains common in clinical practice [4], and
this aspect has not improved over the past 40 years [5].
This has prompted international organizations of clini-
cians and health care providers to recognize the impor-
tance of patient education by healthcare professionals
(HCPs) [6]. The Global Initiative for Asthma (GINA)
Guidelines recommend training patients in the use of
inhalers as a fundamental and essential component of
CONTACT David B. Price dprice@opri.sg Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Forester-
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good clinical practice and consequently advise that HCPs
assess and train patients in inhaler use at every clinical
encounter [7]. Research has shown that face-to-face train-
ing substantially improves patients’ ability to use their
inhalers correctly [8,9]. However, as shown by previous
studies, many HCPs lack the basic knowledge and tech-
nical skill to teach different inhaler techniques [10–12],
and they seldom receive formal training in the use of
inhalers [13]. Finding solutions to this major problem is
of utmost importance to improve the control of asthma
and COPD in the population [14]. While it is important
to explore the way in which HCPs are currently trained in
the use of inhalers, at present it is unfortunately unrealis-
tic to believe that (as is the requirement for patients) each
HCP will have the opportunity to receive hands-on indi-
vidualized training. This puts the onus on each individual
©  Taylor & Francis Group, LLC
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HCP, and this is where more intuitive devices might be of
help. Many of the newer devices are reported to be eas-
ier to use [15–17]; however, it is still unknown what this
actually means for HCPs. While HCPs have been shown
to retain device mastery more efficiently when they have
the opportunity to educate their patients [18], it appears
important to assess the impact of newer and allegedly
more intuitive devices on their ability to retain mastery
over time.
The aim of this study was to assess the nature and
extent of training required for HCPs to master and main-
tain correct inhaler technique when using two different
dry powder inhalers (DPIs), in particular comparing the
role of newer, reportedly simpler to use DPIs with that of
more established DPIs.
Methods
Study design and subjects
This was a multi-center, randomized, un-blinded,
crossover study conducted between July 2014 and June
2015 (ClinicalTrials.gov Identifier: NCT02570425). The
study was approved by the Human Research Ethics
Committees of the University of Sydney (Project No.:
2014/344) and was performed in accordance with
the National Health and Medical Research Council’s
(NHMRC) National Statement on Ethical Conduct in
Human Research (2007) Australia and with the principles
of the Declaration of Helsinki. The sampling frame was
all undergraduate Bachelor of Pharmacy students (Year
1) from the University of Sydney (Australia), Bachelor
of Nursing Students (Year 1) from the University of
Sydney, Doctor of Medicine Students (Year 2) from the
University of Sydney, and Doctor of Medicine Students
(Year 2) from the University of New South Wales, Aus-
tralia. Participants were recruited via relevant e-learning
websites, promotion of the study at lectures, and pro-
vision of participant information at tutorials. Students
who chose to participate in the study, and who provided
written informed consent, were screened for eligibility
and enrolled if they met the following inclusion criteria:
were willing to comply with study restrictions and attend
study visits as specified; and were enrolled in one of the
specified University departments. Potential participants
were excluded from the study if they had a current diag-
nosis of asthma, a past diagnosis of asthma, or both; or
if they had used or received training in the use of either
Turbuhaler R© or Spiromax R© in the last 6 months.
Study devices
Turbuhaler R© and Spiromax R© empty devices were used
for this study. Turbuhaler R© (Astra Zeneca, Sweden) is a
multidose DPI consisting of a protective cover, mouth-
piece, drug reservoir with dose indicator, and a rotating
grip at the base; dose preparation requires holding the
device in the upright position and a full rotation of the
grip [19]. Spiromax R© (Teva Pharmaceutical Industries,
Petach Tikva, Israel) is a multidose DPI with a design
similar to that of a pressurized metered-dose inhaler
(pMDI) but uses an X-ACT R© technology for drug deliv-
ery [20]. Dose preparation consists of opening the cap
until one click is heard while holding the device with the
mouthpiece cover at the bottom [21]. For both devices,
we compiled a checklist of errors potentially impairing
drug delivery to the lungs. These errors were identified a
priori based on the manufacturer’s instructions included
in the patient information leaflet [19,21] and on expert
steering committee advice [22]. The checklists include
errors associated with dose preparation, position of the
inhaler, inhalation maneuver, and general knowledge of
device use (Table S1).
Study procedures
The study consisted of three visits over a period of 8 ±
2 weeks. At each visit, and before starting any procedure,
baseline data (demographic characteristics and history of
inhaler device use prior to study) were collected.
At visit 1, participants were randomly assigned to
either Turbuhaler R© training followed by Spiromax R©
training or Spiromax R© training followed by Turbuhaler R©
training (crossover design) (Figure 1). The training proce-
dure was designed to represent best clinical practice, cur-
rent available mode of education, and to address the edu-
cational needs of HCPs. It consisted of a stepwise process
in which participants were assessed on their ability to use
the device through 6 consecutive steps: (1) intuitive use;
(2) use of patient information leaflet; (3) use of instruc-
tional video; (4) expert tuition; and (5–6) repeats of expert
tuition (Table S2 for details of instructions provided at
each step). At each step, participants were monitored by
expert assessors specifically trained to provide education
and feedback to device users; errors in device use were
recorded according to the device checklist (Table S1). Par-
ticipants progressed from one step to the next until they
achieved device mastery (defined as the ability to demon-
strate inhaler use without assessor-observed errors) or
until completion of all 6 training steps (Figure 2). They
then proceeded to complete the same training and assess-
ment process with the second empty device. At the end of
the visit, participants were asked to rate their satisfaction
for each device by completing Part II question 15 of the
Patient Satisfaction and Preference Questionnaire (PAS-
APQ). PASAPQ is a multi-item measure of satisfaction
and preference for respiratory inhalation devices [23].
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Figure . Overall study design. At visit , participants were randomly assigned to either Spiromax R© training followed by Turbuhaler R©
training or Turbuhaler R© training followed by Spiromax R© training, in a crossover stage design. Training consisted of  consecutive steps
until device mastery was achieved, as shown in Figure . At visits  and , which commenced  ±  week and  ±  weeks after visit ,
respectively, participants undertook the same training procedure.
Visits 2 and 3 commenced 4 weeks (±1 week) and
8 weeks (±2 weeks) after visit 1, respectively. Partic-
ipants were once again randomly assigned to receive
step-by-step device training on Turbuhaler R© followed by
Spiromax R© or Spiromax R© followed by Turbuhaler R© to
determine whether device mastery had been maintained
over the 4- and 8-week time period. If they did not main-
tain device mastery at step 1, participants were trained as
in visit 1 until device mastery was re-established. Device
preference was again assessed using the PASAPQ Part II
question 15 at the end of the visit.
Study definitions and outcomes
Device mastery (yes/no) was defined as the ability
to demonstrate inhaler use without assessor-observed
errors. Maintenance of device mastery, assessed at vis-
its 2 and 3, was defined as the ability to demonstrate
correct inhaler use without the need to undertake any fur-
ther training (i.e., no errors at step 1).
The primary outcome wasmaintenance of device mas-
tery at visit 2. Secondary outcomes includedmaintenance
of device mastery at visit 3 and, for each visit, the follow-
ing: achievement of device mastery by steps 1, 2, and 3;
number of steps required to achievemastery; number and
type of errors made; and participants’ preference for the
inhaler.
Statistical analyses
Data were analyzed using Statistical Analysis Software
version 9.3 (SAS Institute Inc.). The study was powered
on the primary outcome, maintenance of device mastery
at visit 2. Based on the results from a similar study [8], a
sample size of 137 pairs (137 subjects evaluated on both
inhalers) was required to have 90% power to detect a
Figure . Inhaler technique assessment and training. At each study visit, participants were assessed on their ability to use the empty study
devices without training followed by training in a stepwise approach. Training consisted of  consecutive steps: step , intuitive use; step ,
use of patient information leaflet; step , use of instructional video; and steps –, expert tuition. Participants progressed from one step to
the next until devicemasterywas achieved (defined as the absence of assessor-observed serious errors) or until all  stepswere completed.
Upon attainment of device mastery, participants proceeded to complete the same training and assessment procedure with the second
empty device. Abbreviations: HCPs= healthcare professionals.
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difference in proportion of subjects maintaining device
mastery of 0.177 (= 0.789–0.612), when the proportion of
discordant pairs is expected to be 0.431 and the method
of analysis is the McNemar’s test of equality of paired
proportions (with a 0.05 two-sided significance level).
Taking into account a dropout rate of 10% between vis-
its, a minimum of 144 pairs was therefore required for
visit 1.
The McNemar’s test was used to compare the propor-
tion of subjects achieving mastery of inhaler technique
between the two devices. Conditional logistic regression
was used to quantify the difference between the two
devices by calculating the odds ratio (OR) for making
a device error for Spiromax R© (with Turbuhaler R© as the
reference device) with a 95% confidence interval (CI).
When CI does not contain 1.00, results are statistically
significant at the 5% level. The chi-square and Wilcoxon
signed-rank tests were used to compare the proportion
of participants achieving device mastery stratified by the
order of randomization and the mean/median number
of levels required to achieve device mastery between
the two devices, respectively. For all analyses where
p-value is provided, statistical significance was set at
0.05.
Summary statistics collected at each visit included:
number of levels required to achieve device mastery,
number and type of assessor-observed errors (total of
errors made at all steps), and device preference. Continu-
ous variables (including age and number of levels taken to
achieve device mastery) were summarized by reporting
their mean/median along with their standard devia-
tions/interquartile range (IQR). Categorical variables
were reported as frequencies and percentage proportions.
In particular, device mastery (yes/no) was expressed
as cumulative number and percentage of participants
achieving device mastery by each training step, unless
otherwise stated. Participant demographic and base-
line characteristics were summarized using descriptive
statistics.
Results
Participant disposition and characteristics
A total of 542 participants were enrolled in the study;
of these, 516 (39% male, mean age 23 ± 5 years) met
the eligibility criteria and were randomized into visit
1. Four hundred ninety-eight and 460 participants were
eligible for visits 2 and 3, respectively. Figure S1 and
Table S3 show the disposition and the demographic
characteristics of participants at each visit of the study,
respectively.
Primary outcome:Maintaining devicemastery at
visit 2
At visit 2, a total of 498 participants were analyzed, and
of these, 317 (64%) had maintained device mastery with
Spiromax R©, compared with 202 (41%) participants who
had maintained device mastery with Turbuhaler R© (p <
0.001;McNemar’s test of paired data) (Table 1). This effect
was independent of device randomization order (Table 1).
The odds of making a device error was significantly lower
for Spiromax R© compared with Turbuhaler R© (OR 0.37
[95% CI 0.28–0.48]).
By steps 2 and 3, a significantly higher number of par-
ticipants achieved mastery in the use of Spiromax R© as
compared with Turbuhaler R© (p < 0.001 and p = 0.022
for steps 2 and 3, respectively; McNemar’s test of paired
data). This effect was associated with device randomiza-
tion order: at both steps, significantly more participants
using Spiromax R© as first device achieved device mastery
compared with participants using Turbuhaler R© as first
device (p< 0.001 and p = 0.007 for steps 2 and 3, respec-
tively; Chi-squared test); however, there was no signifi-
cant difference in device mastery when Spiromax R© and
Turbuhaler R© were used as second device (step 2, p =
0.347; step 3, p = 1.00) (Table 1). The median number of
steps required to achieve device mastery was 1 (intuitive
use; IQR 1–2) for Spiromax R© and 2 (patient information
leaflet; IQR 1–2) for Turbuhaler R© (p < 0.001, Wilcoxon
signed-rank test).
Secondary outcomes
Achieving devicemastery at visit 
At visit 1, the odds of making a device error prior to
training was significantly lower for Spiromax R© compared
with Turbuhaler R© (OR 0.16 [95% CI 0.10–0.27]). A total
of 113 (22%) participants demonstrated device mastery
at step 1 on Spiromax R© compared with 20 (4%) partic-
ipants achieving mastery on Turbuhaler R© (p < 0.001;
McNemar’s test of paired data) (Table 2). Likewise, a sig-
nificantly higher number of participants achievedmastery
in the use of Spiromax R© by steps 2 and 3 (p< 0.001). This
effect was independent of device randomization order
(steps 1 and 2, p < 0.001 for both randomization orders;
step 3, p< 0.05 for both randomization orders; chi-square
test) (Table 2). By step 4 (expert tuition), about 90% of
participants achieved device mastery, with no statistical
difference between the devices (data not shown).
At visit 1, the median number of steps required to
achieve device mastery was 2 (patient information leaflet;
[IQR] 2–4) for Spiromax R© and 3 (instructional video;
IQR 2–4) for Turbuhaler R© (p < 0.001; Wilcoxon signed-
rank test).
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Table . Participants maintaining and achieving device mastery at Visit .
Maintenance of device mastery
Irrespective of randomization order First randomized device Second randomized device
Training step
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-value∗
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
: Intuitive use (no
training)
 ()  () <.  ()  () <.  ()  () <.
Achievement of device mastery
: Patient
information
leaflet
 ()  () <.  ()  () <.  ()  () .
: Instructional
video
 ()  () .  ()  () .  ()  () .
Note. Data are expressed as cumulative n (%) of participants maintaining/achieving devicemastery by each step. Device mastery (yes/no) was defined as the ability
to demonstrate inhaler use without assessor-observed errors. Steps – are not displayed, as no significant difference was detected between the devices at these
steps.
∗McNemar’s test of paired data.
†Chi-square test.
Table . Participants achieving device mastery at Visit .
Irrespective of randomization order First randomized device Second randomized device
Training step
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value∗
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
: Intuitive use (no
training)
 ()  () <.  ()  () <.  ()  () <.
: Patient
information leaflet
 ()  () <.  ()  () <.  ()  () <.
: Instructional video  ()  () <.  ()  () .  ()  () .
Note. Data are expressedas cumulativen (%)of participants achievingdevicemasterybyeach step.Devicemastery (yes/no)wasdefinedas theability todemonstrate
inhaler use without assessor-observed errors. Steps – are not displayed, as no significant difference was detected between the devices at these steps.
∗McNemar’s test of paired data.
†Chi-square test.
Maintaining devicemastery at visit 
At visit 3, a total of 362 (79%) participants main-
tained device mastery on Spiromax R© prior to training
compared with 299 (65%) participants who main-
tained device mastery on Turbuhaler R© (p < 0.001;
McNemar’s test of paired data); this effect was inde-
pendent of device randomization order (Table 3).
The odds of making a device error was significantly
lower for Spiromax R© compared with Turbuhaler R©
(OR 0.50 [95% CI 0.37–0.68]).
Table . Participants maintaining and achieving device mastery at Visit .
Maintenance of device mastery
Irrespective of randomization order First randomized device Second randomized device
Training step
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value∗
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
Turbuhaler R©
(n= )
Spiromax R©
(n= ) p-Value†
: Intuitive use (no
training)
 ()  () <.  ()  () .  ()  () <.
Achievement of device mastery
: Patient
information
leaflet
 ()  () .  ()  () .  ()  () .
: Instructional
video
 ()  () .  ()  () .  ()  () .
Note. Data are expressed as cumulative n (%) of participants maintaining/achieving devicemastery by each step. Device mastery (yes/no) was defined as the ability
to demonstrate inhaler use without assessor-observed errors. As at steps –, at steps – (not shown) as well, no significant difference was detected between the
devices.
∗McNemar’s test of paired data.
†Chi-square test.
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Figure . Proportion of participants achieving and maintaining
device mastery over the study period. The chart shows the cumu-
lative proportion (%) of participants demonstrating correct inhaler
techniquewith the two studydevices at each stepduring the study
visits. Total number of participants: visit , n= ; visit , n= ;
and visit , n= .
Already by step 2, over 90% of participants demon-
strated device mastery on both inhalers with no signifi-
cant difference between the two devices (Table 3). Like-
wise, there was no significant difference in the median
number of steps required to achieve device mastery
between the two devices (median number of steps 1, IQR
1–1 for Spiromax R© and 1–2 for Turbuhaler R©; p = 0.111,
Wilcoxon signed-rank test).
Figure 3 summarizes the proportion of participants
achieving and maintaining device mastery over the study
period.
Number and types of errors made
At each visit, a higher number of errors were made on
Turbuhaler R© than on Spiromax R© (meannumber of errors
per user, across all steps: 4.9 vs 2.8 at visit 1; 1.6 vs 0.7
at visit 2; 0.6 vs 0.4, at visit 3). The most common device
errorsmade at each visit are reported in Table 4. The error
“not twisting the base as far as possible” (related to dose
preparation) was the most common for Turbuhaler R© at
visits 1 and 2 (made by 389 [75%] and 155 [31%] par-
ticipants, respectively) and the second most common at
visit 3 (Table 4). The error “inhalation not as fast as possi-
ble from the start” (in inhalation maneuver) was the most
common for Spiromax R© at all visits (337 [65%], 96 [19%]
and 50 [11%] at visits 1, 2, and 3, respectively). This error
was one of the most frequent errors for Turbuhaler R© as
well (reported for 323 [63%] and 107 [22%] participants
at visits 1 and 2, respectively). Finally, errors related to
inhaler positionwere common for both inhalers (Table 4).
Participants’ preference for the inhaler
At visit 1, 487 (94%) participants completed question 15
of the PASAPQ PART II. Of these, 74% rated Spiromax R©
as their preferred device compared with 16% who rated
Turbuhaler R© as their preferred device (10% of partic-
ipants reported no preference). Also at visits 2 and 3,
Spiromax R© was the preferred device over Turbuhaler R©
(75% vs 16% at visit 2 [9% no preference], 79% vs 14%
at visit 3 [7% no preference]).
Discussion
We conducted a randomized, un-blinded, crossover study
assessing the nature and extent of training required for
undergraduate HCPs to master inhaler technique and
maintain it over time when using different DPI devices.
In particular, we compared the role of newer, reportedly
easier to use devices (Spiromax R© in this study), with that
of more established devices (Turbuhaler R© in this study).
These two particular inhalers were chosen as relevant
comparators on the basis that they are both DPIs licensed
in Europe for the delivery of budesonide/formoterol com-
bination therapy for asthma but differ in terms of design
and dose preparation steps. We found that undergradu-
ate HCPs demonstrated fewer device errors and required
fewer training steps to master inhaler technique when
using Spiromax R© compared with Turbuhaler R©. Once
established, a higher number of HCPs maintained mas-
tery with Spiromax R© than with Turbuhaler R© over a
period of 2 months. Given that not all HCPs are regular
inhaler users, and that there has been an upsurge of new
inhalers on the market over the last few years, this study
was crucial to understanding how and when undergradu-
ateHCPs need to have their inhaler technique skills devel-
oped and refreshed. We believe that this knowledge will
help to develop strategies to better support HCPs in the
management of patients with respiratory diseases.
Sandler et al. [15] have recently shown that Spiromax R©
is more intuitive to use compared with Turbuhaler R© and
Easyhaler R© when tested in healthy volunteers naïve to all
three devices. Our data on device mastery show that this
is the case also for undergraduate HCPs. This may be due
to the fact that Spiromax R© has fewer preparation steps
for dose delivery. In our study, a large number of par-
ticipants failed to correctly demonstrate dose preparation
steps for Turbuhaler R© (twisting the base as far as possi-
ble and holding the device upright); Spiromax R© does not
require all these steps for preparing the dose. In terms of
the level of training required to achieve mastery, we made
the following observations: (1) at visit 1, 60% of partic-
ipants using Spiromax R© achieved mastery with written
information, whereas for Turbuhaler R©, a video instruc-
tion was required for a comparable proportion of partici-
pants to achieve mastery; (2) although many participants
were able to achieve device mastery after the first three
steps of training, some participants did require additional
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Table . Most common device errors at each visit.
Visit  (participants= )
Turbuhaler R© Spiromax R©
Type of error Description n (%)
∗
Type of error Description n (%)
∗
Dose preparation Not twisting the base as far as
possible until it clicks and not
turning it back to the original
position
 () Inhalation maneuver Inhalation not as fast as possible
from the start
 ()
Position Inhaler not held upright
(mouthpiece pointed skyward
±°) when a dose is prepared
 () Position Inhaler not held upright (±° is
correct) when a dose is prepared
 ()
Inhalation maneuver Inhalation not as fast as possible
from the start
 () General knowledge Fails to put in mouth and seal lips
around mouthpiece
 ()
Visit  (participants= )
Dose preparation Not twisting the base as far as
possible until it clicks and not
turning it back to the original
position
 () Inhalation maneuver Inhalation not as fast as possible
from the start
 ()
Position Inhaler not held upright
(mouthpiece pointed skywards
±°) when a dose is prepared
 () Position Inhaler not held upright (±° is
correct) when a dose is prepared
 ()
Inhalation maneuver Inhalation not as fast as possible
from the start
 () General knowledge Puts finger (or face) over the air
inlet during an inhalation (at
front above the mouthpiece)
 ()
Visit  (participants= )
Position Inhaler not held upright
(mouthpiece pointed skywards
±°) when a dose is prepared
 () Inhalation maneuver Inhalation not as fast as possible
from the start
 ()
Dose preparation Not twisting the base as far as
possible until it clicks and not
turning it back to the original
position
 () General knowledge Puts finger (or face) over the air
inlet during an inhalation (at
front above the mouthpiece)
 ()
Position Inhaler not held upright
(mouthpiece pointed skywards
±°) after the base is twisted
until inhalation
() Position Inhaler not held upright (±° is
correct) when a dose is prepared
 ()
Note. The table shows the distribution of most common types of errors made at each visit, at all steps.
∗Number and % of participants who made the error.
training through individualized feedback to achieve mas-
tery. These findings have practical implications as they
suggest that for Spiromax R©, the written instructions pro-
vided in package inserts are sufficient to train a substan-
tial percentage of individuals, whereas for Turbuhaler R©,
many individuals will need video instructions or demon-
stration by trained HCPs to learn how to use the device
correctly. Further, while video instructions are often pro-
vided on both manufacturers’ and patients’ websites, pro-
viding expert tuition would require allocating specific
resources for the training of HCPs. From this perspective,
it may be important to determine the cost effectiveness
of delivering personalized training to HCPs for different
inhalers.
Inhalers that are more intuitive/easier to use may
paradoxically increase the risk of errors in subsequent
usage, i.e. subjects who demonstrate correct technique
or achieve device mastery with little training in the first
place may do so by chance and therefore may not per-
form as well at subsequent visits; by contrast, subjects
who need more inputs/training may achieve a better
understanding of the device and thus perform better in
the future. However, when reassessing device mastery
1 month and 2 months after initial training, we found
that a higher number of participants maintained correct
technique on Spiromax R© than on Turbuhaler R©. This sug-
gests that once the technique is established for easier-to-
use inhalers, HCPs may be able to maintain mastery over
time with no or little additional training.
Nonetheless, it should be noted that 1 and 2 months
after the initial training, a high percentage of participants
demonstrated correct technique with both devices after
refreshing their skills via written instructions. This indi-
cates that if proper training is provided initially, educat-
ing HCPs to refresh their skills periodically via minimal
instructions may have a big impact on their ability to use
inhalers correctly, and subsequently train patients appro-
priately, in the long term.
The superior ease of use may explain why the major-
ity of participants rated Spiromax R© as their preferred
device compared with Turbuhaler R©. Similar results were
reported by studies that compared device preference
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between Spiromax R© and Turbuhaler R© among healthy
volunteers [15] and patients with asthma [24]. This may
have implications for clinical practice, as patients’ prefer-
ence may affect adherence and thus is an important fac-
tor that HCPs are encouraged to consider when prescrib-
ing/switching inhalers [25].
When taking randomization order into account, we
observed a learning effect. During initial training (visit
1), for both Spiromax R© and Turbuhaler R©, the percentage
of participants demonstrating device mastery when the
inhaler was used as the second device was higher than
the percentage of participants demonstrating mastery
when the inhaler was used as the first device. This was
true for steps 1, 2, and 3, though at step 1, the percentage
increased by three and six times for Spiromax R© and
Turbuhaler R©, respectively. This suggests that there may
be “carry-over” effects in terms of generic skills of inhaler
use. The presence of any “carry-over” effect needs to
be explored in future research and the implications for
practice considered.
When considering the errors, participants made
fewer errors when using Spiromax R© than when using
Turbuhaler R©. Throughout the study, the errors remained
generally consistent for both devices though, as expected,
less frequent. The most common error for Turbuhaler R©
was “not twisting the base as far as possible until it clicks
and not turning it back to the original position,” which
relates to dose preparation and thus is crucial to ensure
correct drug delivery. “Inhalation not as fast as possi-
ble from the start” was the third most common error for
Turbuhaler R© and themost common error for Spiromax R©,
and was displayed by a similar proportion of participants
for the two devices. Failure to inhale as fast as possible is a
common error for DPIs [22,25,26]; thus, the similar num-
ber of users demonstrating this error with either device is
as expected. Because correct inhalation technique is criti-
cal to appropriatemedication intake, HCPs should be par-
ticularly mindful of this error when training patients in
the use of anyDPI. It should be noted that although “hold-
ing the inhaler in the upright position (±90°) during dose
preparation” was included in the manufacturer’s instruc-
tions for Spiromax R© at the time in which this research
was performed, a recent study [20] has shown that dose
consistency is maintained with Spiromax R© regardless of
device orientation (±45° tested in addition to ±90°). In
light of this, this position error may not represent a criti-
cal error for Spiromax R©.
Basheti et al. [27] have recently addressed the issue
of heterogeneity of error checklists in the field and pro-
vided recommendations about standardized checklists for
two DPIs, Diskus R© and Turbuhaler R©. The list used for
Turbuhaler R© in the present study followed their recom-
mendations, and although such recommendations are not
currently available for themore recent device Spiromax R©,
our checklists were generated by expert opinion and
included errors that have been used in previous studies
[15]. The errors considered here are those commonly seen
in clinical practice, which have potential implications on
device effectiveness; however, they are not a validated
measure. Although some studies have investigated the
impact of inhaler misuse or the number of inhaler errors
on asthma control [4,26] andmanagement [2], knowledge
of the relationship between individual inhaler errors and
asthmaoutcomes is still limited. This knowledgewould be
crucial to better identify critical errors and develop edu-
cational interventions for HCPs and patients tailored to
address such errors specifically.
There are some limitations in the study design. This
was primarily an “evaluation-of-concept” study that ana-
lyzed a cohort of undergraduate HCPs with a mean age
of 23. This is a very specific cohort, and thus our findings
may not be generalizable to patients with chronic airways
disease or to practicing HCPs.
Conclusions
This study shows that there are significant differences in
the nature and extent of training required for HCPs to
achieve and maintain mastery with different DPI devices.
Inhalers that are easier to use may facilitate achieve-
ment of device mastery and its maintenance over time.
Expert tuition during initial training may help to opti-
mise HCP knowledge of inhaler use to the extent that
refreshing HCP skills with minimal instructions (such as
written instructions) may be sufficient to maintain cor-
rect technique over time. Future research should explore
the impact of tailored education for HCPs on the health
care system in terms of clinical and economic outcomes.
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